Suzhou Smartnuclide Biopharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has entered into a business cooperation agreement with Shenzhen China Resources Gosun Pharmaceuticals Co., Ltd, granting the latter exclusive market promotion rights for its recombinant human thyroid stimulating hormone (rhTSH) in the thyroid and breast surgery markets within China. The financial terms of the agreement have not been disclosed.
The rhTSH product, designed to rapidly elevate TSH levels in the body, holds promise for various indications such as adjuvant therapy for iodine [131I] clearance of residual thyroid tissue in patients with non-distant metastatic differentiated thyroid cancer (DTC) post-total or near-total thyroidectomy. Additionally, it aids in serum thyroglobulin (Tg) adjuvant diagnosis in patients with differentiated thyroid cancer during follow-up after thyroidectomy. The market filing for this product was submitted to the Center for Drug Evaluation (CDE) in July 2022, with market approval anticipated in the near future.- Flcube.com
